Biotech Values

[Mpower]

This is precisely my point. The market is irrational undervaluing MNTA on the mere threat of a impending lawsuit. A lawsuit would guarantee MNTA 5-$6 EPS as the sole generic for at least 2-3 years, because the FDA will not get scared into approving TEVA's generic. The stock was trading at $16.5 a few weeks before approval, now under a sole generic (best case) scenario (with hundreds of millions pouring in) its trading at $15... huh... that smells fishy to me.

A 10 year old would understand that, but people on this board are telling me the the market is pricing MNTA efficiently. That defies common sense.